Metabolism and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor apatinib in humans

Drug Metabolism and Disposition

Volumn 41, Issue 6, 2013, Pages 1195-1210

  Ding, Juefang ^a   Chen, Xiaoyan ^a   Gao, Zhiwei ^a   Dai, Xiaojian ^a   Li, Liang ^a   Xie, Cen ^a   Jiang, Haoyuan ^b   Zhang, Lijia ^b   Zhong, Dafang ^a  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

^b Jiangsu Hengrui Medicine Co Ltd   (China)

Author keywords

[No Author keywords available]

Indexed keywords

3 HYDROXY 16 HYDROXY N DEALKYLATED; 3 HYDROXY 25 N OXIDE; 3 HYDROXY APATINIB; 3 HYDROXY APATINIB O GLUCURONIDE; 3 HYDROXY O GLUCURONIDE N DEALKYLATED; ANGIOGENESIS INHIBITOR; APATINIB; APATINIB 25 N OXIDE; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; DRUG METABOLITE; FLAVINE CONTAINING MONOOXYGENASE; GLUCURONOSYLTRANSFERASE 2B7; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; RECOMBINANT ENZYME; STEM CELL FACTOR; SULFAPHENAZOLE; UNCLASSIFIED DRUG; UNSPECIFIC MONOOXYGENASE; VASCULOTROPIN RECEPTOR 2;

ADULT; AEROBIC METABOLISM; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; DEALKYLATION; DOSE TIME EFFECT RELATION; DRUG CLEARANCE; DRUG CONJUGATION; DRUG ELIMINATION; DRUG EXCRETION; DRUG EXPOSURE; DRUG FECES LEVEL; DRUG GLUCURONIDATION; DRUG HALF LIFE; DRUG HYDROXYLATION; DRUG METABOLISM; DRUG OXIDATION; DRUG PROTEIN BINDING; DRUG RETENTION; DRUG STRUCTURE; DRUG URINE LEVEL; ENZYME ASSAY; ENZYME KINETICS; FEMALE; HUMAN; IC 50; IN VITRO STUDY; LIVER MICROSOME METABOLISM; MALE; MASS FRAGMENTOGRAPHY; MAXIMUM PLASMA CONCENTRATION; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; SINGLE DRUG DOSE; STEADY STATE; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADULT; AGED; FEMALE; HUMANS; MALE; MICROSOMES, LIVER; MIDDLE AGED; PYRIDINES; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; YOUNG ADULT;

EID: 84878228694     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.112.050310     Document Type: Article

References (34)

1. Carmeliet P and Jain RK (2000) Angiogenesis in cancer and other diseases. Nature 407:249-257.
2. Chelucci G, Baldino S, Pinna GA, Benaglia M, Buffa L, and Guizzetti S (2008) Chiral pyridine N-oxides derived from monoterpenes as organocatalysts for stereoselective reactions with allyltrichlorosilane and tetrachlorosilane. Tetrahedron 64:7574-7582.
3. Degrauwe N, Sosa JA, Roman S, and Deshpande HA (2012) Vandetanib for the treatment of metastatic medullary thyroid cancer. Clin Med Insights Oncol 6:243-252.
4. Ding J, Chen X, Dai X, and Zhong D (2012) Simultaneous determination of apatinib and its four major metabolites in human plasma using liquid chromatography-tandem mass spectrometry and its application to a pharmacokinetic study. J Chromatogr B Analyt Technol Biomed Life Sci 895-896:108-115.
5. El-Mekkawy S, Meselhy MR, Kawata Y, Kadota S, Hattori M, and Namba T (1993) Metabolism of strychnine N-oxide and brucine N-oxide by human intestinal bacteria. Planta Med 59:347-350.
6. Gennigens C and Jerusalem G (2012) [Pazopanib (Votrient) in the management of renal cell cancer and soft tissue sarcomas]. Rev Med Liege 67:437-442.
7. Glade-Bender J, Kandel JJ, and Yamashiro DJ (2003) VEGF blocking therapy in the treatment of cancer. Expert Opin Biol Ther 3:263-276.
8. Heinrich MC, Blanke CD, Druker BJ, and Corless CL (2002) Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies. J Clin Oncol 20:1692-1703.
9. Hunt JT, Mitt T, Borzilleri R, Gullo-Brown J, Fargnoli J, Fink B, Han WC, Mortillo S, Vite G, and Wautlet B, et al. (2004) Discovery of the pyrrolo[2, 1-f][1, 2, 4]triazine nucleus as a new kinase inhibitor template. J Med Chem 47:4054-4059.
10. Irby RB and Yeatman TJ (2000) Role of Src expression and activation in human cancer. Oncogene 19:5636-5642.
11. Ivy SP, Wick JY, and Kaufman BM (2009) An overview of small-molecule inhibitors of VEGFR signaling. Nat Rev Clin Oncol 6:569-579.
12. Izzedine H, Rixe O, Billemont B, Baumelou A, and Deray G (2007) Angiogenesis inhibitor therapies: focus on kidney toxicity and hypertension. Am J Kidney Dis 50:203-218.
13. Kulanthaivel P, Barbuch RJ, Davidson RS, Yi P, Rener GA, Mattiuz EL, Hadden CE, Goodwin LA, and Ehlhardt WJ (2004) Selective reduction of N-oxides to amines: application to drug metabolism. Drug Metab Dispos 32:966-972.
14. Leclercq L, Cuyckens F, Mannens GS, De Vries R, Timmerman P, and Evans DC (2009) Which human metabolites have we MIST? Retrospective analysis, practical aspects, and perspectives for metabolite identification and quantification in pharmaceutical development. Chem Res Toxicol 22:280-293.
15. Lessard E, Hamelin BA, Labbé L, O'Hara G, Bélanger PM, and Turgeon J (1999) Involvement of CYP2D6 activity in the N-oxidation of procainamide in man. Pharmacogenetics 9:683-696.
16. Li C, Kuchimanchi M, Hickman D, Poppe L, Hayashi M, Zhou Y, Subramanian R, Kumar G, and Surapaneni S (2009) In vitro metabolism of the novel, highly selective oral angiogenesis inhibitor motesanib diphosphate in preclinical species and in humans. Drug Metab Dispos 37:1378-1394.
17. Li J, Zhao X, Chen L, Guo H, Lv F, Jia K, Yv K, Wang F, Li C, and Qian J, et al. (2010) Safety and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor YN968D1 in patients with advanced malignancies. BMC Cancer 10:529-536.
18. Mano Y, Usui T, and Kamimura H (2007a) Predominant contribution of UDP-glucuronosyltransferase 2B7 in the glucuronidation of racemic flurbiprofen in the human liver. Drug Metab Dispos 35:1182-1187.
19. Mano Y, Usui T, and Kamimura H (2007b) The UDP-glucuronosyltransferase 2B7 isozyme is responsible for gemfibrozil glucuronidation in the human liver. Drug Metab Dispos 35:2040-2044.
20. Mi YJ, Liang YJ, Huang HB, Zhao HY, Wu CP, Wang F, Tao LY, Zhang CZ, Dai CL, and Tiwari AK, et al. (2010) Apatinib (YN968D1) reverses multidrug resistance by inhibiting the efflux function of multiple ATP-binding cassette transporters. Cancer Res 70:7981-7991.
21. Ohno S and Nakajin S (2009) Determination of mRNA expression of human UDP-glucuronosyltransferases and application for localization in various human tissues by realtime reverse transcriptase-polymerase chain reaction. Drug Metab Dispos 37:32-40.
22. Olesen OV and Linnet K (1999) Studies on the stereoselective metabolism of citalopram by human liver microsomes and cDNA-expressed cytochrome P450 enzymes. Pharmacology 59:298-309.
23. 7) nicotinic acetylcholine receptor agonist in humans. Drug Metab Dispos 35:1188-1195.
24. Smith DA and Obach RS (2005) Seeing through the mist: abundance versus percentage: commentary on metabolites in safety testing. Drug Metab Dispos 33:1409-1417.
25. Song S, Ewald AJ, Stallcup W, Werb Z, and Bergers G (2005) PDGFRbeta+ perivascular progenitor cells in tumours regulate pericyte differentiation and vascular survival. Nat Cell Biol 7:870-879.
26. Tang JR, Markham NE, Lin YJ, McMurtry IF, Maxey A, Kinsella JP, and Abman SH (2004) Inhaled nitric oxide attenuates pulmonary hypertension and improves lung growth in infant rats after neonatal treatment with a VEGF receptor inhibitor. Am J Physiol Lung Cell Mol Physiol 287:L344-L351.
27. Tian S, Quan H, Xie C, Guo H, Lü F, Xu Y, Li J, and Lou L (2011) YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo. Cancer Sci 102:1374-1380.
28. Tong XZ, Wang F, Liang S, Zhang X, He JH, Chen XG, Liang YJ, Mi YJ, To KK, and Fu LW (2012) Apatinib (YN968D1) enhances the efficacy of conventional chemotherapeutical drugs in side population cells and ABCB1-overexpressing leukemia cells. Biochem Pharmacol 83:586-597.
29. Tugnait M, Hawes EM, McKay G, Rettie AE, Haining RL, and Midha KK (1997) N-oxygenation of clozapine by flavin-containing monooxygenase. Drug Metab Dispos 25:524-527.
30. Uchaipichat V, Mackenzie PI, Elliot DJ, and Miners JO (2006) Selectivity of substrate (trifluoperazine) and inhibitor (amitriptyline, androsterone, canrenoic acid, hecogenin, phenylbutazone, quinidine, quinine, and sulfinpyrazone) "probes" for human udp-glucuronosyltransferases. Drug Metab Dispos 34:449-456.
31. Verbeke N, Pellegrin P, Vienne A, and Lesne M (1979) The binding of gitoxin to human plasma proteins. Eur J Clin Pharmacol 16:341-344.
32. Zhang H, Zhu M, Ray KL, Ma L, and Zhang D (2008) Mass defect profiles of biological matrices and the general applicability of mass defect filtering for metabolite detection. Rapid Commun Mass Spectrom 22:2082-2088.
33. Zhou D, Zhang M, Ye X, Gu C, Piser TM, Lanoue BA, Schock SA, Cheng YF, and Grimm SW (2011) In vitro metabolism of a7 neuronal nicotinic receptor agonist AZD0328 and enzyme identification for its N-oxide metabolite. Xenobiotica 41:232-242.
34. Zhou SF, Liu JP, and Lai XS (2009) Substrate specificity, inhibitors and regulation of human cytochrome P450 2D6 and implications in drug development. Curr Med Chem 16:2661-2805.